Navigation Links
Clinical Research Study Focuses on Little Known Behavioral Changes Related to Parkinson's Disease
Date:1/22/2009

Study Recruiting Adult Parkinson's Patients with Behavioral Changes

KING OF PRUSSIA, Pa., Jan. 22 /PRNewswire/ -- Parkinson's disease affects 6.3 million people worldwide. While the disease is recognized for its profound effects on movement such as tremors, less known is that 1 in 3 Parkinson's disease patients will develop changes that include hallucinations, illusions and delusions.

ACADIA Pharmaceuticals, a biopharmaceutical company headquartered in San Diego is currently conducting a study aimed at improving the quality of life for people with Parkinson's disease and its behavioral complications. The company recently received an award from the Michael J. Fox Foundation for its continuing work in Parkinson's research.

ACADIA Pharmaceuticals is now evaluating an investigational medication that researchers hope will help treat the cognitive and behavioral changes caused by Parkinson's. As Parkinson's disease progresses, up to 40 percent of patients can experience what is called 'Parkinson's Psychosis.' A condition in which patients experience changes in thought, behavior and judgment that can have devastating effects. In more advanced stages these symptoms include hallucinations, illusions and delusions where patients see things that aren't really there, believe things that are untrue, create false ideas and falsely accuse those closest to them.

"While the physical manifestations of Parkinson's disease are difficult to deal with, the changes in thought, behavior and judgment strain the bonds between patients and their caregivers and families," said expert Dr. Bernard Ravina, Director of the Movement and Inherited Neurological Disorders Unit at the University of Rochester in New York.

An online survey conducted by MediciGlobal, a firm assisting ACADIA Pharmaceuticals in finding Parkinson's patients with Psychosis for this study, found that 4 out of every 10 Parkinson's caregivers were unaware that these behavioral and cognitive changes were associated with Parkinson's. Carol McLain, a registered nurse and caregiver who responded to the survey said, "As a nurse, I was prepared for the physical problems but I was totally unprepared for the psychiatric issues in caring for my husband."

There are currently no FDA-approved treatments for these particular non-physical symptoms of Parkinson's disease. Research is necessary to advance future medicines for Parkinson's Psychosis.

Those caring for someone who may be experiencing Parkinson's Disease Psychosis, are encouraged to call the toll-free study hotline , at 1-866-565-0261 or visit the clinical research Web site at www.ParkinsonsMindStudy.com. Here caregivers can find clinical research centers conducting this study.


'/>"/>
SOURCE MediciGlobal
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study
2. Life Sciences Organizations Choose Oracle to Accelerate and Simplify Clinical Trial Data Collection
3. REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)
4. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
5. Inverseons Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet
6. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
7. First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer
8. Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium
9. Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
10. MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
11. Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Scientists at the University of Athens ... for mesothelioma may be hampering the research that could lead to one good one. ... to read it now. , The team evaluated 98 mesothelioma patients ...
(Date:5/25/2016)... Connecticut (PRWEB) , ... May 25, 2016 , ... ... the U.S. Food and Drug Administration (FDA) has granted the company’s orphan drug ... the company’s second orphan drug designation granted by the FDA. , Spinocerebellar ...
(Date:5/24/2016)... La Jolla, CA (PRWEB) , ... May 24, 2016 , ... ... and financial planning for corporate executives and entrepreneurs, held The Future of San Diego ... leaders in the San Diego life science community attended the event with speakers Dr. ...
(Date:5/23/2016)... ... May 23, 2016 , ... PrecisionAg® Media has ... 2017 and Beyond. The paper outlines the key trends that are creating both ... “We’ve witnessed a lot of highs and lows as the precision agriculture market ...
Breaking Biology Technology:
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
(Date:3/15/2016)... -- Yissum Research Development Company of the Hebrew ... Hebrew University, announced today the formation of Neteera ... human biological indicators. Neteera Technologies has completed its first ... ... emissions from sweat ducts, enables reliable and speedy biometric ...
(Date:3/11/2016)... -- --> --> ... Market by Technology (Pattern Recognition), by Component (Hardware, Software, ... (On-Premises and Cloud), by Industry Vertical and by Region ... global market is expected to grow from USD 12.49 ... at a CAGR of 19.1%. , ...
Breaking Biology News(10 mins):